Qu Biologics
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4475 Wayburne Dr Ste 305, Burnaby, Briti...Phone Number
(604) 734-1450Website
www.qubiologics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Qu Biologics
Qu Biologics is at the forefront of developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform aimed at restoring normal immune function to combat cancer, chronic inflammatory diseases, and metabolic disorders. Their innovative approach leverages the body's natural immune response, targeting specific organs to address immune dysfunction associated with various diseases. Currently, Qu Biologics is conducting a Phase 2 clinical trial to evaluate the efficacy of their QBECO SSI in preventing post-operative immune suppression in late-stage colon cancer patients. The company is committed to transforming treatment paradigms and advancing the potential of SSIs across multiple health conditions.Explore more
Qu Biologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Qu Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Qu Biologics has new funding data
Check if Qu Biologics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Qu Biologics launches new products
Earning: See what the market has to say on Qu Biologics recently announced quarterly report
Qu Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Qu Biologics
Website visits: Recent activity has been detected on your website
Click to see if Qu Biologics had a recent Job posting/layoffs
Check out if Qu Biologics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Qu Biologics
Find 2 more new buyers
Compare Similar Companies to Qu Biologics
Compare insights from companies similar to Qu Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Qu Biologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Qu Biologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Qu Biologics.
Qu Biologics financials insights
Gather financial insights about Qu Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$4.6M
2015
Private Equity
$2.5M
2016
Private Equity
$3.1M
2020
Other Financing Round
$8M
2022
Unspecified
$12M
Qu Biologics Tech Stack
A closer look at the technologies used by Qu Biologics
Most Recent Scoops
Person-Based
Hiring Plans
Qu Biologics has more open roles in Clinical Operations than it has had at any time in the past 12 months.
Open Position
New Hire
Executive Move
Funding
Qu Biologics News & Media
Qu Biologics’ Immunomodulator Clears Senescence
BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation platform designed to restore innate immune function, is pleased to report exciting data demonstrating that its QBECO immunomodulator lowers a key indicator of senescence in the liver of animals with established obesity.Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation platform designed to restore innate immune function, is pleased to report exciting data demonstrating that Qu Biologics’ QBECO SSI markedly improves fatty liver disease and its deleterious consequences in an animal model of preexisting obesity. The study was conducted in collaboration with Dr. Jon SchQu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report exciting survival data using a combination of Qu Biologics’ QBECO SSI and CAR T-cell therapy in laboratory models of aggressive cancer. The study was conducted in collaboration with the Yong Loo Lin School of Medicine, NationaSeniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to strengthen natural immunity among seniors aged 65 or older, is enrolling participants in the study.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Qu Biologics
Sign Up For FreeTo access detailed company insights
Qu Biologics is at the forefront of developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform aimed at restoring normal immune function to combat cancer, chronic inflammatory diseases, and metabolic disorders. Their innovative approach leverages the body's natural immune response, targeting specific organs to address immune d... Read More
